Search

BACKGROUND: Some sodium-glucose co-transporter-2 (SGLT2) inhibitors showed benefits on heart failure (HF), but different SGLT2/SGLT1 selectivity might influence the treatment effect. This study aimed to meta-analyze the treatment effects of SGLT2 inhibitors and the diversity of receptor selectivity for patients with and without HF. METHODS: Randomized controlled trials were searched in PubMed, Embase, Cochrane databases and ClinicalTrials.gov registry from inception to October 2020. The interest outcomes were analyzed with random-effects models and presented with a risk ratio (RR) and 95% confidence interval (CI). Subgroup analyses examined the treatment effects among SGLT2 inhibitors with different SGLT2/SGLT1 selectivity. RESULTS: The final analyses included 10 trials and 52,607 patients. The RR of total cardiovascular (CV) death or hospitalization for HF (HHF) between SGLT2 inhibitors and placebo was 0.79 (95% CI 0.74-0.84, I2 = 31%). With SGLT2 inhibitors, HF patients had reduced mortality risks (RR 0.89, 95% CI 0.80-0.99, I2 = 0), and non-HF patients had lower risks of major adverse CV events (RR 0.92, 95% CI 0.85-0.99, I2 = 0). The risk reduction of HHF was consistent in groups of HF (RR 0.72, 95% CI 0.64-0.80, I2 = 8%) and non-HF (RR 0.74, 95% CI 0.61-0.89, I2 = 0), but the effect of the low SGLT2/SGLT1 selectivity inhibitor was insignificant in non-HF patients. CONCLUSION: The efficacy of SGLT2 inhibitors on risk reduction of total CV death or HHF is consistent with the previous studies. The regimen is beneficial for reducing mortality in patients with HF and major adverse CV events in those without HF. Different SGLT2/SGLT1 selectivity may differ in the treatment effects in patients with and without HF. ispartof: MEDICINE vol:101 issue:51 ispartof: location:United States status: published

Additional file 2: Overview of detailed model structure of cost-effectiveness analysis where adverse events of treatment were considered.

Additional file 6: Subgroup analyses based on (a) race, (b) age, (c) type 2 diabetes mellitus (T2DM) status, (d) New York Heart Association functional class (NYHA Fc), (e) left ventricular ejection fraction (LVEF), and (f) history of ischemic heart failure (HF).

Additional file 9: Observed and simulated survival curves of patients with stable heart failure.

Additional file 1: Overview of detailed model structure of base-case cost-effectiveness analysis.

Additional file 8: Cost-effectiveness of add-on dapagliflozin to standard care versus standard care alone in Asia-Pacific countries.

Additional file 7: Probability of cost-effectiveness of adding dapagliflozin to standard care versus standard care alone under different monthly costs of dapagliflozin.

Additional file 4: Cost and utility inputs for cost-effectiveness analysis of add-on dapagliflozin to standard care versus standard care alone in other Asia-Pacific countries.

Additional file 5: Scatter plot of distribution of incremental cost and effectiveness ratios under the willingness-to-pay threshold of US$ 25,000 in Taiwan.

Additional file 3 Study parameters associated with hospitalizations for adverse events of treatments in the simulation model (sensitivity analysis).